Poseida Therapeutics: A Strong Buy on Robust Pipeline, Strategic Partnerships, and Leadership Enhancements

William Blair analyst Sami Corwin has maintained their bullish stance on PSTX stock, giving a Buy rating on May 10.

Sami Corwin has given his Buy rating due to a combination of factors surrounding Poseida Therapeutics that indicate potential for growth and value creation. The company has demonstrated progress in its genetic medicines pipeline, notably with its liver-directed gene editor, which showed promising preclinical editing efficiency. Furthermore, Poseida’s collaboration with Roche, marked by a recent $30 million payment and an additional upcoming milestone payment, underscores the financial and strategic support behind its development efforts.
Moreover, the appointment of Dr. Syed Rizvi as chief medical officer, with his relevant experience at Caribou Biosciences, suggests a strengthening of Poseida’s leadership in advancing its cell therapy programs. Anticipated updates on clinical trials, including the Phase I/II trial of P-BCMA-ALLO1 in multiple myeloma and initial data from the Phase I trial of P-CD19CD20-ALLO1 in B-cell malignancies, provide upcoming catalysts that could enhance investor confidence. The planned initiation of IND-enabling work for a new prostate cancer treatment further diversifies Poseida’s portfolio and presents additional avenues for growth.

In another report released on May 10, Piper Sandler also reiterated a Buy rating on the stock with a $10.00 price target.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Poseida Therapeutics (PSTX) Company Description:

Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumors.